December 21, 2019 : Issue #1021

Exclusive: Coming Soon? Oral Insulin

Oral Insulin (ORMD-0801) Close to Reality

TOP STORIES — Diabetes News and Research

Diabetes Risks Using Glucocorticoids

The First Automated Insulin Dosing Controller FDA Approved 

We have been following the introduction of a new oral GLP-1 analog from Novo. Although oral seems easy, the dosing schedule may be a problem that will hold up adoption.

Now there is news of an oral insulin, from Oramed Pharmaceuticals, that is moving closer to approval. Will it be a simple drug to use or will it have dosing issues? This week our publisher, Steve Freed, sits down with Oramed Pharmaceuticals’ CEO Nadav Kidron and Dr. Joel Neutel, Principal Investigator of the study, in an exclusive interview find out what the future holds and when we can expect to “swallow our insulin.”

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

An interview with Oramed Pharmaceuticals CEO and Principal Investigator about a Phase 2b study of its oral insulin and the latest clinical results.

Glucocorticoids (GC) may expose patients to the risk of diabetes, particularly with long term use.

This approval is an example of artificial intelligence being used to improve the health of our patients with diabetes and will get us closer to a true artificial pancreas.

Scientific evidence suggests an association between psoriasis and cardiovascular and metabolic diseases. However, there are hardly any sex‐specific results from population‐based studies reporting the prevalence of cardiovascular risk factors in patients with psoriasis and point estimates of the association between psoriasis and cardiovascular and metabolic disorders. The purpose of the study was to evaluate the sex‐specific prevalence of psoriasis and cardiovascular risk factors and to estimate sex‐specific associations between psoriasis and diabetes type 2 (DM) and metabolic syndrome (MetS). The results were based on 3723 individuals ages 45 to 75. The researchers found that the prevalence of psoriasis was 3.8 percent, with no differences between men and women. Metabolic and cardiovascular risk factors were more common in women with psoriasis versus women without psoriasis. However, in men, this pattern was partly reversed. There were distinctly elevated prevalence rates (PRs) for type 2 diabetes for both women and men with psoriasis. For metabolic syndrome, the results were inconsistent, with a positive association between psoriasis and metabolic syndrome in women but a negative association in men. The results of the cross‐sectional, population‐based analysis showed a distinct association between psoriasis and DM.  Researchers also discovered that metabolic syndrome was positively and negatively associated with psoriasis among women and men, respectively.

Journal of the European Academy of Dermatology and Venereology

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Andrew Daoud, PharmD Candidate, Florida A&M University

Emma Kammerer, L|E|C|O|M Bradenton School of Pharmacy, PharmD Candidate

Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.